Document is current
Any future updates will be listed below
-
Authors
Pearson, Alexander T. https://orcid.org/0000-0003-2801-7456
Muzaffar, Jameel
Kirtane, Kedar
Bellile, Emily
Suresh, Krithika https://orcid.org/0000-0001-7785-3536
Rosenberg, Ari J. https://orcid.org/0000-0001-5908-0939
Worden, Francis
Chung, Christine H. https://orcid.org/0000-0001-5199-4306
Vokes, Everett
Brenner, J. Chad https://orcid.org/0000-0003-3238-1111
Bhangale, Apurva https://orcid.org/0000-0001-7262-569X
McHugh, Jon
Warner, Kristy
Nor, Felipe
Nor, Jacques E.
Innes, Keri
Zhai, Yifan
Fu, Tommy
Swiecicki, Paul L. https://orcid.org/0000-0003-2286-3555
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P3O CA046592)
Ascentage Pharma Group Corp Ltd. (Hong Kong) provided research funding and supply of study drug to the University of Michigan.
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01-DE021139)
- License Information
-
More Information
Article History
Received: 26 September 2025
Accepted: 2 March 2026
First Online: 19 March 2026
Competing interests
: ATP- Consulting or Advisory Role: Thermofisher, Breakthrough Cancer, Caris, AbbVie. Research Fund from AbbVie, IBM unrelated to this work. JM- Consulting or Advisory Role: Exelexis, RAPT therapeutics, FENNEC pharmaceuticals. KK- Consulting or Advisory Role: MyCareGorithm. Stock Ownership: Oncternal Therapeutics, Veru unrelated to this work. AJR- Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas, Regeneron, Galectin, Privo Technologies, Adela, RAPT Therapeutics, GeoVax, Janssen, Exelixis, Bicara, Summit Therapeutics, Corbus, Coherus Biosciences. FW- No competing interests. CC- Consulting or Advisory Role: AVEO, Bicara Therapeutics, Exelixis, Fulgent, Genmab, Regeneron, Seagen, and Johnson & Johnson. EV- Consulting or Advisory Role: AbbVie, AstraZeneca, BioNTech, Boehringer-Ingelheim, Day One, Eikon Therapeutics, Genmab, GlaxoSmithKline, Marengo, Merus, MJH Lifesciences, Translational Drug Development LLC. YZ and TF are employees of Ascentage Pharma Group Inc. and shareholders in its parent company, Ascentage Pharma Group International. YZ also holds a leadership role within the company and has two patents related to the study—one granted (US11850239B2, “MDM2 inhibitor and a platinum compound for cancer treatment”) and the other pending (US20250195473A1, “Combination of immunotherapies with MDM2 inhibitors”). P.S.- Consulted or Advisory Role: Remix Therapeutics, Elevar Therapeutics, Prelude Therapeutics, CDR-Life, Astellas, JNJ, and Regeneron.
: Selected data were presented as an oral plenary presentation at the 2024 Multidisciplinary Head and Neck Cancers Symposium co-sponsored by ASTRO (American Society for Radiation Oncology), ASCO (American Society of Clinical Oncology), AHNS (American Head and Neck Society), and SITC (Society for Immunotherapy of Cancer).
